Q3 Earnings Forecast for ALGS Issued By HC Wainwright

Key Points

• HC Wainwright forecasts Aligos Therapeutics' Q3 2025 earnings at ($2.26) per share, maintaining a "Buy" rating and a $50.00 price target.
• The company's recent earnings report showed a loss of ($1.53) per share, surpassing expectations of ($2.35) by $0.82, with revenue of $0.97 million.
• Institutional investors hold 60.43% of Aligos Therapeutics stock, with significant increases in positions by Geode Capital Management and Adage Capital Partners.

Aligos Therapeutics, Inc. (NASDAQ:ALGS - Free Report) - Equities researchers at HC Wainwright issued their Q3 2025 earnings per share (EPS) estimates for shares of Aligos Therapeutics in a report issued on Monday, August 18th. HC Wainwright analyst P. Trucchio anticipates that the company will post earnings of ($2.26) per share for the quarter. HC Wainwright has a "Buy" rating and a $50.00 price objective on the stock. The consensus estimate for Aligos Therapeutics' current full-year earnings is ($10.36) per share. HC Wainwright also issued estimates for Aligos Therapeutics' Q4 2025 earnings at ($2.29) EPS, FY2025 earnings at ($8.19) EPS, Q1 2026 earnings at ($2.33) EPS, Q2 2026 earnings at ($2.45) EPS, Q3 2026 earnings at ($1.95) EPS, Q4 2026 earnings at ($2.04) EPS, FY2026 earnings at ($8.66) EPS, FY2027 earnings at ($6.81) EPS, FY2028 earnings at ($6.38) EPS and FY2029 earnings at ($6.26) EPS.

Aligos Therapeutics Price Performance

Shares of ALGS traded up $0.3310 on Wednesday, reaching $10.5310. 76,374 shares of the stock traded hands, compared to its average volume of 169,020. The firm has a market cap of $64.77 million, a price-to-earnings ratio of -0.53 and a beta of 2.77. Aligos Therapeutics has a 12 month low of $3.76 and a 12 month high of $46.80. The stock's 50-day moving average price is $8.19 and its 200-day moving average price is $9.12.

Aligos Therapeutics (NASDAQ:ALGS - Get Free Report) last issued its quarterly earnings results on Wednesday, August 6th. The company reported ($1.53) EPS for the quarter, topping the consensus estimate of ($2.35) by $0.82. The company had revenue of $0.97 million for the quarter, compared to the consensus estimate of $0.43 million. Aligos Therapeutics had a negative return on equity of 22.41% and a negative net margin of 2,337.24%.

Institutional Trading of Aligos Therapeutics

A number of large investors have recently bought and sold shares of the stock. Tower Research Capital LLC TRC grew its position in Aligos Therapeutics by 2,073.3% in the fourth quarter. Tower Research Capital LLC TRC now owns 652 shares of the company's stock valued at $26,000 after acquiring an additional 622 shares during the period. Golden State Wealth Management LLC boosted its stake in Aligos Therapeutics by 100.0% in the first quarter. Golden State Wealth Management LLC now owns 5,348 shares of the company's stock worth $44,000 after purchasing an additional 2,674 shares in the last quarter. Geode Capital Management LLC boosted its stake in Aligos Therapeutics by 13.3% in the fourth quarter. Geode Capital Management LLC now owns 27,253 shares of the company's stock worth $1,086,000 after purchasing an additional 3,197 shares in the last quarter. Northern Trust Corp acquired a new position in Aligos Therapeutics in the fourth quarter worth $205,000. Finally, XTX Topco Ltd acquired a new position in Aligos Therapeutics in the second quarter worth $100,000. 60.43% of the stock is currently owned by institutional investors.

About Aligos Therapeutics

Aligos Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in viral and liver diseases. Its drug candidate, ALG-055009, a small molecule THR-ß agonist that is in the Phase 2a clinical trial for the treatment of non-alcoholic steatohepatitis (NASH).